Cadrenal Therapeutics, Inc. (CVKD) Stock Price & Analysis

CVKD Stock Chart & Stats

$0.99$0.04(4.45%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $0.94 - $1.00
52-Week Range: $0.82 - $13.75
Previous Close: $0.94
Volume: 28.12K
Average Volume (3M): 172.48K
Market Cap: $3.51M
Enterprise Value: $7.34M
Total Cash (Recent Filing): $2.39M
Total Debt (Recent Filing): $0
Price to Earnings (P/E): ―
Beta: 0.96
Next Earnings: Nov 05, 2026 (Est.)
EPS Estimate: -0.91
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress

FDA alignment on the Phase 3 design reduces regulatory uncertainty around CAD-1005 and provides a clearer development pathway. Agreement on endpoints and analysis may improve trial execution and strengthen the asset’s attractiveness to potential partners.

Pipeline Breadth

Multiple programs across acute, chronic and inflammatory cardiovascular settings give Cadrenal more than one potential source of future value. This breadth can support partnering flexibility and reduce reliance on a single clinical asset over the next several quarters.

Low Leverage

An effectively debt-free balance sheet limits interest and refinancing pressure while positive equity indicates progress from the prior deficit. This provides more financial flexibility than a highly leveraged structure as the company advances clinical programs.

Bears Say

Pre-Revenue Losses

The absence of revenue means Cadrenal has not yet demonstrated commercial traction or operating leverage, while widening losses show that development spending continues to outpace any inflows. Earnings remain dependent on future clinical and commercialization success.

Persistent Cash Burn

Sustained operating and free-cash-flow deficits require Cadrenal to fund research and operations before revenue generation begins. Continued deterioration in cash generation can constrain development choices and increase dependence on future financing or strategic transactions.

Potential Dilution

The approved equity awards and warrant shares provide financing and compensation flexibility but can increase the share count if issued or exercised. Potential dilution may reduce existing holders’ ownership percentage while the company remains pre-revenue and capital dependent.

Cadrenal Therapeutics, Inc. News

Cadrenal Therapeutics Begins Strategic Review of Orphan Portfolio

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an update. On October 7, 2026, Cadrenal Therapeutics said its board had launched a formal strategic review to maximize the value of

3w ago8K CVKD

Cadrenal Therapeutics initiates process to evaluate opportunities

Cadrenal Therapeutics (CVKD) announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio. The

3w agoCVKD

Cadrenal Shareholders Approve Equity Plan and Board Changes

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has shared an announcement. At its Annual Meeting of Stockholders on September 24, 2026, Cadrenal Therapeutics, Inc. secured shareholder approval to amend its 2022

1M ago8K CVKD

Regulatory Clarity and De-Risked Phase 3 Plan Support Cadrenal Buy Rating, $13 Target Unchanged

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cadrenal Therapeutics, Inc. today and set a price target of $13.00. Joseph Pantginis has given his Buy rating due to

2M agoCVKD

Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has provided an announcement. On August 31, 2026, Cadrenal Therapeutics reported positive feedback from a July 28, 2026 FDA Type D meeting that clarified

2M ago8K CVKD

Cadrenal Therapeutics gets feedback from CAD-1005 Type D Meeting with FDA

Cadrenal Therapeutics (CVKD) announced feedback from a Type D Meeting with the FDA held on July 28. During the meeting, Cadrenal and the FDA aligned on aspects of the protocol

2M agoCVKD

Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Cadrenal Therapeutics, Inc., retaining the price target of $13.00. Joseph Pantginis has given his Buy rating due to a

2M agoCVKD

Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy

An update from Cadrenal Therapeutics, Inc. ( ($CVKD) ) is now available. Cadrenal Therapeutics, Inc., a late-stage biopharmaceutical player in critical care cardiology and orphan cardiovascular diseases, has built a

3M ago8K CVKD

Cadrenal Therapeutics Announces Chief Medical Officer Transition

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has issued an announcement. On July 14, 2026, Cadrenal Therapeutics entered into a confidential separation agreement with Chief Medical Officer James J. Ferguson III,

3M ago8K CVKD

Cadrenal Therapeutics files to sell 2.94M shares of common stock for holders

17:12 EDT Cadrenal Therapeutics (CVKD) files to sell 2.94M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

3M agoCVKD

Cadrenal Therapeutics announces clinical data from CAD-1005 study

Cadrenal Therapeutics (CVKD) announced that late-breaking clinical data from the Phase 2 study of the 12-lipoxygenase inhibitor CAD-1005 were featured in a highly anticipated late-breaking oral presentation at the International

3M agoCVKD

Cadrenal Therapeutics Announces Chief Medical Officer Resignation

Cadrenal Therapeutics, Inc. ( ($CVKD) ) has provided an announcement. On July 7, 2026, Cadrenal Therapeutics disclosed that Chief Medical Officer James J. Ferguson III had submitted his resignation, with

3M ago8K CVKD

Cadrenal Therapeutics Secures Private Placement to Extend Runway

Cadrenal Therapeutics, Inc. ( ($CVKD) ) just unveiled an announcement. On June 30, 2026, Cadrenal Therapeutics entered a definitive agreement with a single healthcare-focused institutional investor for a private placement

4M ago8K CVKD

Cadrenal Names Interim CFO, Realigns Board Structure

The latest update is out from Cadrenal Therapeutics, Inc. ( ($CVKD) ). On June 25, 2026, Cadrenal Therapeutics appointed veteran finance executive John P. Sharp as interim chief financial officer

4M ago8K CVKD

CVKD FAQ

What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?

Cadrenal Therapeutics, Inc. lowest stock price was $0.82 and its highest was $13.75 in the past 12 months.

What is Cadrenal Therapeutics, Inc.’s market cap?

Cadrenal Therapeutics, Inc.’s market cap is $3.51M.

When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?

Cadrenal Therapeutics, Inc.’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 4 days.

How were Cadrenal Therapeutics, Inc.’s earnings last quarter?

Cadrenal Therapeutics, Inc. released its earnings results on Aug 13, 2026. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.42 by $0.28.

Is Cadrenal Therapeutics, Inc. overvalued?

According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.

Does Cadrenal Therapeutics, Inc. pay dividends?

Cadrenal Therapeutics, Inc. does not currently pay dividends.

What is Cadrenal Therapeutics, Inc.’s EPS estimate?

Cadrenal Therapeutics, Inc.’s EPS estimate is -0.91.

How many shares outstanding does Cadrenal Therapeutics, Inc. have?

Cadrenal Therapeutics, Inc. has 3,567,592 shares outstanding.

What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?

Cadrenal Therapeutics, Inc. reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.42. Following the earnings report the stock price went up 0.538%.

Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?

Hedge funds hold Cadrenal Therapeutics, Inc. shares: the largest hedge-fund position in Cadrenal Therapeutics, Inc. is 71,888,421 shares, and hedge funds decreased their holdings by 5.5K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description